Literature DB >> 9238034

Mouse mammary tumor virus/v-Ha-ras transgene-induced mammary tumors exhibit strain-specific allelic loss on mouse chromosome 4.

E H Radany1, K Hong, S Kesharvarzi, E S Lander, J M Bishop.   

Abstract

Hybrid mice carrying oncogenic transgenes afford powerful systems for investigating loss of heterozygosity (LOH) in tumors. Here, we apply this approach to a neoplasm of key importance in human medicine: mammary carcinoma. We performed a whole genome search for LOH using the mouse mammary tumor virus/v-Ha-ras mammary carcinoma model in female (FVB/N x Mus musculus castaneus)F1 mice. Mammary tumors developed as expected, as well as a few tumors of a second type (uterine leiomyosarcoma) not previously associated with this transgene. Genotyping of 94 anatomically independent tumors revealed high-frequency LOH ( approximately 38%) for markers on chromosome 4. A marked allelic bias was observed, with M. musculus castaneus alleles almost exclusively being lost. No evidence of genomic imprinting effects was noted. These data point to the presence of a tumor suppressor gene(s) on mouse chromosome 4 involved in mammary carcinogenesis induced by mutant H-ras expression, and for which a significant functional difference may exist between the M. musculus castaneus and FVB/N alleles. Provisional subchromosomal localization of this gene, designated Loh-3, can be made to a distal segment having syntenic correspondence to human chromosome 1p; LOH in this latter region is observed in several human malignancies, including breast cancers. Evidence was also obtained for a possible second locus associated with LOH with less marked allele bias on proximal chromosome 4.

Entities:  

Mesh:

Year:  1997        PMID: 9238034      PMCID: PMC23068          DOI: 10.1073/pnas.94.16.8664

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

1.  Identification of hepatocarcinogen-resistance genes in DBA/2 mice.

Authors:  G H Lee; L M Bennett; R A Carabeo; N R Drinkwater
Journal:  Genetics       Date:  1995-01       Impact factor: 4.562

2.  Insertional mutagenesis identifies a member of the Wnt gene family as a candidate oncogene in the mammary epithelium of int-2/Fgf-3 transgenic mice.

Authors:  F S Lee; T F Lane; A Kuo; G M Shackleford; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

3.  Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2.

Authors:  P W Janes; R J Daly; A deFazio; R L Sutherland
Journal:  Oncogene       Date:  1994-12       Impact factor: 9.867

4.  Genome-wide search for loss of heterozygosity in transgenic mouse tumors reveals candidate tumor suppressor genes on chromosomes 9 and 16.

Authors:  W F Dietrich; E H Radany; J S Smith; J M Bishop; D Hanahan; E S Lander
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

5.  A tumor suppressor gene on chromosome 1p32-pter controls the amplification of MYC family genes in breast cancer.

Authors:  I Bièche; M H Champème; R Lidereau
Journal:  Cancer Res       Date:  1994-08-15       Impact factor: 12.701

6.  Genetic analysis of liver tumorigenesis in SV40 T antigen transgenic mice implies a role for imprinted genes.

Authors:  W A Held; J Pazik; J G O'Brien; K Kerns; M Gobey; R Meis; L Kenny; Y Rustum
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

7.  Chromosome 8 alterations accompany tumorigenesis in renin-SV40 T antigen transgenic mice.

Authors:  W A Held; J G O'Brien; K Kerns; J F Gallagher; C D Sigmund; K W Gross
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

8.  Loss of Apc+ in intestinal adenomas from Min mice.

Authors:  C Luongo; A R Moser; S Gledhill; W F Dove
Journal:  Cancer Res       Date:  1994-11-15       Impact factor: 12.701

9.  Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation.

Authors:  M E Hegi; T R Devereux; W F Dietrich; C J Cochran; E S Lander; J F Foley; R R Maronpot; M W Anderson; R W Wiseman
Journal:  Cancer Res       Date:  1994-12-01       Impact factor: 12.701

10.  A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway.

Authors:  R Ben-Levy; H F Paterson; C J Marshall; Y Yarden
Journal:  EMBO J       Date:  1994-07-15       Impact factor: 11.598

View more
  4 in total

1.  Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.

Authors:  Jason I Herschkowitz; Wei Zhao; Mei Zhang; Jerry Usary; George Murrow; David Edwards; Jana Knezevic; Stephanie B Greene; David Darr; Melissa A Troester; Susan G Hilsenbeck; Daniel Medina; Charles M Perou; Jeffrey M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-01       Impact factor: 11.205

2.  A role for BRCA1 in uterine leiomyosarcoma.

Authors:  Deyin Xing; George Scangas; Mai Nitta; Lei He; Xuan Xu; Yevgeniya J M Ioffe; Paul-Joseph Aspuria; Cyrus Y Hedvat; Matthew L Anderson; Esther Oliva; Beth Y Karlan; Gayatry Mohapatra; Sandra Orsulic
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

Review 3.  Pre-clinical applications of transgenic mouse mammary cancer models.

Authors:  C J Kavanaugh; K V Desai; A Calvo; P H Brown; C Couldrey; R Lubet; J E Green
Journal:  Transgenic Res       Date:  2002-12       Impact factor: 2.788

4.  Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation.

Authors:  A Claeskens; N Ongenae; J M Neefs; P Cheyns; P Kaijen; M Cools; E Kutoh
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.